Use of Adiana Tubal Occlusive Devices in Women With Hydrosalpinx Prior to In Vitro Fertilization

Reproductive Science Center

Status and phase: Unknown; Phase 2

Conditions: Women Suffering From Unilateral or Bilateral Tubal Occlusion Due to Hydrosalpinx

Treatments: Device: Adiana placement

Study type: Interventional

Funder types: Industry

Identifiers

NCT01224080

IVF-002

Details and patient eligibility

About

A condition called hydrosalpinx occurs when one or both of the fallopian tubes is blocked with fluid. The fluid can leak into the tube and the uterus. The theory is that the fluid can harm the tubes and uterus making implantation more difficult or harm the embryo.

Enrollment: 10 estimated patients

Sex: Female

Ages: 21 to 43 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Are willing to participate in this clinical study
• Are able to comprehend and give informed consent for participation in this study
• Have read, understood and signed an informed consent form
• Have been unable to achieve pregnancy after trying for 1 year or greater and who have unilateral or bilateral hydrosalpinges as evidenced by laparoscopy or ultrasound or HSG
• Have a Day #3 serum FSH<10, and Day #3 Estradiol<80
• Recipient women undergoing a ovum donor cycle the donor must have a Day 3 serum FSH < 10 and Day 3 Estradiol < 80
• Have an antral follicle count 10 or greater for both ovaries combined, if women using ovum donor (follicle count) will be based on eligible donor
• Have a desire to receive treatment for their HS
• Are willing to undergo a hysterosalpingogram (HSG) 3 months after ADIANA placement to confirm proximal tubal occlusion

Exclusion criteria

• Active or recent upper or lower pelvic infection
• Known hypersensitivity to nickel as confirmed by skin test
• Known allergy to contrast media
• Pregnancy or suspected pregnancy
• Delivery or termination of pregnancy less than six weeks prior to Adiana placements
• BMI > 35
• Abnormal pap smear (CIN2 or greater abnormality) within the past year
• Pelvic malignancy
• Severely retroverted uterus
• Evidence of intrauterine abnormalities such as submucous fibroids, polyps, intrauterine adhesions or presence of a uterine septum
• Abnormal Clomid Challenge Test or abnormal lab values on Day #3 serum FSH and Estradiol
• Antral follicle count less than 10 (both ovaries combined)
• Poor general or gynecologic health
• Inability or refusal to provide informed consent

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Adiana Device

Experimental group

Description:

All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.

Treatment:

Device: Adiana placement